Literature DB >> 9177493

p53 gene mutations in soft-tissue sarcomas--correlations with p53 immunohistochemistry and DNA ploidy.

R Schneider-Stock1, K Radig, Y Oda, W Mellin, J Rys, A Niezabitowski, A Roessner.   

Abstract

The significance of p53 mutations in a group of 67 soft-tissue tumors was examined using single-strand conformation polymorphism and direct sequencing analysis. Molecular findings were correlated with immunohistochemical detection of the p53 protein and DNA ploidy status. Mutations of the p53 gene were detected in 13 (19.5%) out of 67 cases of soft-tissue tumors. Only three were localized outside the conservative regions of the p53 gene. Six mutations were described for the first time in these tumors. Most of the mutations were point mutations in exons 5-8 and, in one case, a deletion at the 3'-splice site of exon 5 could be demonstrated. There was no significant correlation between the occurrence of p53 mutations and the histological grade, although a high number of mutations were defined in poorly differentiated tumors (grade 3). Molecular finding of a p53 gene mutation and immunohistochemical detection of p53 expression did not correlate, which may be due to the high percentage of nonsense mutations in our study (50%). We confirm that only DNA sequencing allows a unique identification and differentiation of mutations in the p53 gene. Other factors may be responsible for the detection of p53 protein in many cases. Histological grade correlated with aneuploidy. The frequency of mutations observed was in accordance with values quoted in the literature. Generally, p53 mutations and p53 overexpression are more likely to represent a late event in the oncogenesis of soft-tissue tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9177493     DOI: 10.1007/BF01240317

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  37 in total

1.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

2.  DNA ploidy in soft tissue tumors: an evaluation of the prognostic implications in the different tumor types.

Authors:  W Mellin; A Niezabitowski; M Brockmann; J Ritter; P Wuisman; V Krieg
Journal:  Curr Top Pathol       Date:  1995

3.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

4.  Overexpression or mutation of the p53 tumor suppressor gene does not occur in malignant ovarian germ cell tumors.

Authors:  F S Liu; E S Ho; J T Chen; R T Shih; C H Yang; A Shih
Journal:  Cancer       Date:  1995-07-15       Impact factor: 6.860

5.  Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas.

Authors:  E Latres; M Drobnjak; D Pollack; M R Oliva; M Ramos; M Karpeh; J M Woodruff; C Cordon-Cardo
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

6.  Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.

Authors:  R Donghi; A Longoni; S Pilotti; P Michieli; G Della Porta; M A Pierotti
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

7.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

Authors:  Y Cho; S Gorina; P D Jeffrey; N P Pavletich
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

8.  Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours.

Authors:  H Kovar; A Auinger; G Jug; D Aryee; A Zoubek; M Salzer-Kuntschik; H Gadner
Journal:  Oncogene       Date:  1993-10       Impact factor: 9.867

9.  p53 abnormalities in different subtypes of human sarcomas.

Authors:  A Andreassen; T Oyjord; E Hovig; R Holm; V A Flørenes; J M Nesland; O Myklebost; J Høie; O S Bruland; A L Børresen
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

Review 10.  The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis.

Authors:  A J Levine; M E Perry; A Chang; A Silver; D Dittmer; M Wu; D Welsh
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

View more
  6 in total

1.  Gliomatosis cerebri: post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide.

Authors:  C Mawrin; V Aumann; E Kirches; R Schneider-Stock; C Scherlach; S Vogel; U Mittler; K Dietzmann; G Krause; S Weis
Journal:  J Neurooncol       Date:  2001-10       Impact factor: 4.130

Review 2.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

3.  Targeting the p53 Pathway in Ewing Sarcoma.

Authors:  Paul M Neilsen; Kathleen I Pishas; David F Callen; David M Thomas
Journal:  Sarcoma       Date:  2010-12-09

4.  Frequent loss of expression or aberrant alternative splicing of P2XM, a p53-inducible gene, in soft-tissue tumours.

Authors:  G Nawa; Y Miyoshi; H Yoshikawa; T Ochi; Y Nakamura
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

5.  A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas.

Authors:  Varun Monga; Umang Swami; Munir Tanas; Aaron Bossler; Sarah L Mott; Brian J Smith; Mohammed Milhem
Journal:  Cancers (Basel)       Date:  2018-02-17       Impact factor: 6.639

6.  Nuclear DNA-Content in Mesenchymal Lesions in Dogs: Its Value as Marker of Malignancy and Extent of Genomic Instability.

Authors:  Kim M Boerkamp; Gerard R Rutteman; Marja J L Kik; Jolle Kirpensteijn; Christoph Schulze; Guy C M Grinwis
Journal:  Cancers (Basel)       Date:  2012-12-03       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.